Take­da takes a swing at RNA small mol­e­cules with dis­cov­ery pact for mul­ti­ple po­ten­tial Evotec pro­grams

Heart­ened by an FDA ap­proval for Roche’s Evrys­di last year as the first small mol­e­cule mod­u­la­tor for RNA, the rest of bio­phar­ma is look­ing to place their bets in the promis­ing field. No stranger to ear­ly-stage dis­cov­ery deals, Take­da has now iced a pact with a Ger­man play­er to chase the first small mol­e­cule lig­and for RNA.

Ger­many-based Evotec will team up with Take­da to dis­cov­er and de­vel­op RNA tar­gets ripe for small mol­e­cule ther­a­peu­tics, the com­pa­ny an­nounced Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER